Developer:	Cypress Bioscience Inc.
Chemical Name:	Milnacipran
Drug Class (Type):	Norepinephrine Serotonin Reuptake Inhibitor (Chemical)
Dose Form:
Indication:	Milnacipran is intended for the treatment of fibromyalgia syndrome.
Disease/Medical Usage:	Fibromyalgia syndrome
Therapeutic Category:	Fibromyalgia treatments
Status:	Phase III clinical trials As of Mar 27, 2006, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Jan 5, 2006, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Nov 9, 2005, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Jul 27, 2005, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Dec 8, 2004, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Jul 12, 2004, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Jan 9, 2004, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Oct 21, 2003, Milnacipran was in Phase III clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Aug 14, 2003, Milnacipran was in Phase II clinical trials in the United States for the treatment of fibromyalgia syndrome.As of April 24, 2003, Milnacipran was in Phase II clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Dec 17, 2002, Milnacipran was in Phase II clinical trials in the United States for the treatment of fibromyalgia syndrome.As of Jul 9, 2002, Milnacipran was in Phase II clinical trials in the United States for the treatment of fibromyalgia syndrome.On Feb 25, 2002, Cypress Bioscience Inc. announced that it has launched Phase II clinical development program for milnacipran for the treatment of fibromyalgia syndrome. Patient recruitment into the trial is expected to begin in March, with a goal of enrolling approximately 200 patients by the end of the year.On Jan 7, 2002, Cypress Bioscience Inc. announced that its investigational new drug application filed in December 2001 with the U.S. Food and Drug Administration is now open, allowing the company to start clinical testing of milnacipran for the treatment of fibromyalgia syndrome.On Dec 6, 2001, Cypress Bioscience announced that it has filed an investigational new drug application with the Food and Drug Administration, to begin Phase II clinical trials of Milnacipran for the treatment of fibromyalgia syndrome.On Aug 13, 2001, Cypress Bioscience, Inc. announced that it planned to begin Phase II clinical trials for Milnacipran, for the treatment of fibromyalgia syndrome, in the US and Canada, in early 2002.
Geographic Region:	United States
Total Sales for 2009:	Not Specified
Last Updated:	March 27, 2006

about us | contact us | home

Powered by

© 2010 Engel Publishing Partners terms of use | privacy | copyright